Breaking News Instant updates and real-time market news.

MCO

Moody's

$94.27

-2.59 (-2.67%)

, GS

Goldman Sachs

$240.42

-2.475 (-1.02%)

10:25
01/10/17
01/10
10:25
01/10/17
10:25

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Moody's (MCO) was downgraded to Equal Weight from Overweight at Barclays and to Neutral from Buy at UBS. 2. Goldman Sachs (GS) and Comerica (CMA) were downgraded to Sell from Neutral at Citi. 3. T-Mobile (TMUS) downgraded to Neutral from Buy at MoffettNathanson. 4. AMAG Pharmaceuticals (AMAG) downgraded to Market Perform from Outperform at Leerink and to Neutral from Buy at Janney Capital. 5. BP (BP) downgraded to Market Perform from Outperform at BMO Capital analyst Brendan Warn citing his belief that the company will make a major acquisition this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MCO

Moody's

$94.27

-2.59 (-2.67%)

GS

Goldman Sachs

$240.42

-2.475 (-1.02%)

CMA

Comerica

$69.42

-0.12 (-0.17%)

TMUS

T-Mobile

$56.67

-0.1 (-0.18%)

AMAG

Amag Pharmaceuticals

$23.00

-12.7 (-35.57%)

BP

BP

$37.22

-0.095 (-0.25%)

  • 10

    Jan

  • 10

    Jan

  • 17

    Jan

MCO Moody's
$94.27

-2.59 (-2.67%)

01/10/17
UBSW
01/10/17
DOWNGRADE
Target $99
UBSW
Neutral
Moody's downgraded to Neutral from Buy at UBS
UBS analyst Alex Kramm downgraded Moody's to Neutral saying the company's 2017 guidance in a few weeks will likely miss consensus estimates. Potential headwinds from tax reform and higher interest rates are not fully priced into the stock's current valuation, Kramm tells investors in a research note. He lowered his price target for the shares to $99 from $116. Barclays this morning also downgraded Moody's.
01/10/17
LEHM
01/10/17
DOWNGRADE
Target $100
LEHM
Equal Weight
Moody's downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Manav Patnaik downgraded Moody's to Equal Weight saying issuance could be pressured by rising interest rates and tax reform while the Department of Justice overhang limits buybacks. The analyst lowered his price target for the shares to $100 from $120.
08/30/16
EVER
08/30/16
NO CHANGE
Target $117
EVER
Hold
Moody's added to Tactical Buy list at Evercore ISI
Evercore analyst Warren Gardiner added Moody's to the Tactical Buy list saying corporate debt issuance trends have exceeded expectations in August and are posed to continue through the fall. The analyst sais structured finance is also finding a footing and combed with some expense flexibility to support a potential issuance drop-off, believes shares have near-term attractive risk/reward. Gardiner rates Moody's a Hold with a $117 price target.
09/21/16
LEHM
09/21/16
UPGRADE
Target $37
LEHM
Overweight
TransUnion upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Manav Patnaik upgraded TransUnion (TRU) to Overweight saying credit bureaus will continue to outperform and that the market will benefit from a "scarcity value" in Industrials. The analyst keeps a $37 price target for the shares. Patnaik calls S&P Global (SPGI) his top pick in Information Services and raised his price target for the shares to $145 from $140. The analyst also views Moody's (MCO) as a "name to own" and upped his price target for the shares to $125 from $120. Patnaik this morning also downgraded Fair Isaac (FICO) to Equal Weight.
GS Goldman Sachs
$240.42

-2.475 (-1.02%)

12/21/16
12/21/16
DOWNGRADE
Target $240

Neutral
Goldman Sachs downgraded due to valuation at Atlantic Equities
As previously reported, Atlantic Equities downgraded Goldman Sachs to Neutral from Overweight. Analyst Christopher Wheeler said Goldman will be a major beneficiary of a better tone to capital markets post-election but said shares have rallied strongly through his $240 price target.
12/21/16
12/21/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) downgraded to Hold from Buy at Stifel with analyst Astrachan citing "recent negative FX movement, moderate anticipated input cost inflation, and continued heightened geopolitical uncertainty." 2. JetBlue (JBLU) downgraded to Market Perform from Outperform at Raymond James with analyst Savanthi Syth saying shares will be range bound near-term due to RASM pressures from capacity growth new market expansion, and increased cost inflation. 3. Barrick Gold (ABX) downgraded to Hold from Buy at TD Securities analyst Greg Barnes saying shares have significantly outperformed in 2016 and sees fewer company-specific catalysts in 2017. 4. New York Community Bancorp (NYCB) and Astoria Financial (AF) were downgraded to Underperform at FBR Capital. 5. Goldman Sachs (GS) and U.S. Bancorp (USB) were downgraded to Neutral from Overweight at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/06/17
UBSW
01/06/17
NO CHANGE
Target $285
UBSW
Buy
Goldman Sachs price target raised to $285 from $234 at UBS
UBS analyst Brennan Hawken raised his price target on Goldman Sachs $285 from $234 citing its earnings power and expectations for the bank to take market share as the revenue environment improves. Hawken reiterated his Buy rating on Goldman Sachs shares.
01/10/17
SBSH
01/10/17
DOWNGRADE
Target $225
SBSH
Sell
Goldman Sachs downgraded to Sell from Neutral at Citi
Citi analyst Keith Horowitz downgraded Goldman Sachs (GS) to Sell with a $225 price target, representing 6% downside from current levels. While higher interest rates benefit fixed income trading, the path is "relatively uncertain and the bar is relatively high" for Goldman, Horowitz tells investors in a research note. The analyst believes U.S. bank stocks do not offer compelling risk/reward profiles following the recent rally. Horowitz this morning also downgraded Comerica (CMA) to Sell while keeping Buy ratings on Wells Fargo (WFC) and Bank of America (BAC).
CMA Comerica
$69.42

-0.12 (-0.17%)

01/04/17
01/04/17
NO CHANGE

Comerica's Texas index improves for second consecutive month
Comerica Bank's Texas Economic Activity Index advanced by 0.4% points in October to a level of 91.0. October's index reading is 18 points, or 25%, above the index cyclical low of 72.8. The index averaged 97.5 points for all of 2015, seven and one-half points below the average for full-year 2014. September's index reading was 90.6. Six out of eight index components were positive in October. nonfarm employment, state exports, unemployment insurance claims (inverted), rig count, home prices and hotel occupancy. Housing starts eased in October for the third consecutive month. State sales tax revenue eased as well. Job growth appears to be stabilizing for Texas, with gains seen for the last eight consecutive months.
01/05/17
JPMS
01/05/17
UPGRADE
Target $80
JPMS
Overweight
Comerica upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Steven Alexopoulos upgraded Comerica to Overweight saying the company benefits more from rising interest rates than the typical bank. The analyst raised his price target for the shares to $80 from $53.
01/10/17
SBSH
01/10/17
DOWNGRADE
Target $65
SBSH
Sell
Comerica downgraded to Sell from Neutral at Citi
Citi analyst Keith Horowitz downgraded Comerica (GS) to Sell with a $65 price target. The rise in interest rates seem more than priced in at current levels, Horowitz tells investors in a research note. The analyst believes U.S. bank stocks do not offer compelling risk/reward profiles following the recent rally.
TMUS T-Mobile
$56.67

-0.1 (-0.18%)

01/05/17
01/05/17
NO CHANGE
Target $11

Outperform
Sprint price target raised to $11 from $8 at FBR Capital
FBR Capital analyst David Dixon raised his price target for Sprint (S) to $11 saying the introduction of higher-power devices this year should drive improved subscriber and free cash flow growth. The passage of the High Power User Equipment by the 3GPP standards body should raise Sprint's spectrum-portfolio value, increasing the asset's appeal across the industry as well as the probability of a merger with T-Mobile (TMUS) under a new Republican-led Administration, Dixon tells investors in a research note. He keeps an Outperform rating on Sprint shares.
01/10/17
MOFT
01/10/17
DOWNGRADE
MOFT
Neutral
T-Mobile downgraded to Neutral from Buy at MoffettNathanson
12/07/16
OPCO
12/07/16
NO CHANGE
Target $70
OPCO
Outperform
T-Mobile price target raised to $70 from $55 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for T-Mobile (TMUS) to $70 from $55 as he views it as the best way to play the deregulatory/technology driven consolidation. The analyst notes that President-Elect Trump met with Masayoshi Son of SoftBank (SFTBF), who agreed to invest $50B in the U.S. Horan believes the meeting will likely be a precursor to a Sprint (S)/T-Mobile/Dish (DISH) merger to create a discounted quad-play service company. The analyst reiterates an Outperform rating on T-Mobile' shares, and points out that the company has improved its network and taken share from AT&T (T)/Verizon (VZ).
12/21/16
OPCO
12/21/16
NO CHANGE
OPCO
T-Mobile could be worth $80/share in potential takeover, says Oppenheimer
Oppenheimer analyst Timothy Horan continues to believe that either Comcast (CMCSA; CMCSK) or Sprint (S) is the likely merger partner for T-Mobile (TMUS), potentially prompting a bidding war. Moreover, the analyst believes it is not unreasonable for Comcast or Sprint to pay $80/share for T-Mobile, or even higher. Commenting on Microsoft's (MSFT) valuation, Horan says he examined the sum of its parts, valuing Azure, its Cloud Software, and "legacy Microsoft" to arrive at a conservative $70 valuation. Additionally, he sees a major inflection in top/bottom-line growth in 2019 as Microsoft's cloud services, specifically Azure, grow more rapidly/profitably than the Wall Street expects.
AMAG Amag Pharmaceuticals
$23.00

-12.7 (-35.57%)

01/10/17
JANY
01/10/17
DOWNGRADE
JANY
Neutral
AMAG Pharmaceuticals downgraded to Neutral from Buy at Janney Capital
01/09/17
RAJA
01/09/17
DOWNGRADE
RAJA
Underperform
AMAG Pharma downgraded to Underperform from Market Perform at Raymond James
01/10/17
LEER
01/10/17
DOWNGRADE
Target $25
LEER
Market Perform
AMAG Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Leerink analyst Joseph Schwartz downgraded AMAG Pharmaceuticals (AMAG) to Market Perform from Outperform after the company provided a "disappointing update" related to the Makena auto-injector program. Furthermore, the analyst notes that the licensing agreement with Palatin (PTN) for its hypoactive sexual desire disorder drug Rekynda could drive incremental value but will require "sizable upfront investment" and have to clear regulatory and commercialization hurdles before that takes place. Nonetheless, Schwartz notes that AMAG's preliminary Q4 results and FY17 financial estimates were in-line with his bullish outlook for 2016-2017. He also lowered his price target on AMAG's shares to $25 from $39.
01/10/17
01/10/17
DOWNGRADE
Target $25

Neutral
AMAG Pharmaceuticals downgraded to Neutral at Janney Capital
As previously reported, Janney Capital analyst Ken Trbovich downgraded AMAG Pharmaceuticals to Neutral from Buy after the company terminated a pain study and surprisingly said it would no longer pursue orphan drug exclusivity for its new Makena subcutaneous formulation. Due to this decision, AMAG will no longer have the benefit of the exclusivity to block generic, or other branded, subcutaneous formulations, said Trbovich, who concluded this makes efforts to switch patients to the new Makena SQ much riskier than he previously expected. Trbovich lowered his fair value estimate on AMAG shares to $25 from $45.
BP BP
$37.22

-0.095 (-0.25%)

01/10/17
BMOC
01/10/17
DOWNGRADE
BMOC
Market Perform
BP downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Brendan Warn downgraded BP based on his belief that the company will make a major acquisition this year.
12/21/16
UBSW
12/21/16
UPGRADE
UBSW
Buy
BP upgraded to Buy from Neutral at UBS
UBS analyst Jonathon Rigby upgraded BP to Buy.
12/21/16
12/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sunoco (SUN) upgraded to Outperform from Neutral at Credit Suisse with analyst John Edwards saying valuation is "underappreciated" and said a dividend cut is unlikely given options available for Sunoco and Energy Transfer Equity (ETE) to execute before reducing payouts. 2. BP (BP) and Statoil (STO) were upgraded to Buy from Neutral at UBS. 3. Citi (C) and Bank of America (BAC) were upgraded to Overweight from Neutral at Atlantic Equities while Morgan Stanley (MS) was upgraded to Neutral from Underweight. 4. Air Products (APD) upgraded to Buy from Neutral at Monness Crespi with the firm saying it thinks that Air Products will benefit from consolidation in the industry. It says that Air Products' balance sheet will enable it to "easily bid on and win new projects" and exploit divestitures in the sector. 5. Monster Beverage (MNST) upgraded to Buy from Hold at Jefferies with analyst Kevin Grundy calling the stock his top large cap growth pick in Consumer Products. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/16
12/28/16
NO CHANGE

Shell Midstream acquires interests in three Gulf of Mexico pipelines from BP
Shell Midstream (SHLX) has acquired 10% interest in Proteus Oil Pipeline Company, 10% interest in Endymion Oil Pipeline Company, and a 1% interest in Cleopatra Gas Gathering Company from BP (BP). The acquisition price reflects an approximate 7.7 times multiple of Shell's forecasted annual average Adjusted EBITDA attributable to the purchased interests over 2017 and 2018. The acquisition was funded with borrowings under Shell Midstream Partners' revolving credit facilities and is expected to be immediately accretive to unitholders. Proteus is a 71-mile crude oil pipeline with a 425,000 bpd capacity. Endymion is an 89-mile crude oil pipeline with a 425,000 bpd capacity. Cleopatra is a 115-mile gas gathering pipeline in Southern Green Canyon, with access to Atwater Valley, Walker Ridge, and Lund areas in the Gulf of Mexico.

TODAY'S FREE FLY STORIES

ATUS

Altice USA

$20.48

0.62 (3.12%)

13:45
11/20/17
11/20
13:45
11/20/17
13:45
Conference/Events
Morgan Stanley European telecom analysts hold analyst/industry conference call »

European Analysts discuss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$19.64

0.14 (0.72%)

13:40
11/20/17
11/20
13:40
11/20/17
13:40
Options
Higher option volume in Hanesbrands driven by a call spread »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$188.16

3.77 (2.04%)

13:30
11/20/17
11/20
13:30
11/20/17
13:30
Initiation
L3 Technologies initiated  »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

RXDX

Ignyta

$14.90

0.05 (0.34%)

13:30
11/20/17
11/20
13:30
11/20/17
13:30
Initiation
Ignyta initiated  »

Ignyta initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

BKD

Brookdale Senior Living

$10.43

0.01 (0.10%)

13:30
11/20/17
11/20
13:30
11/20/17
13:30
Options
Bullish option play in Brookdale Senior Living »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$90.42

-0.06 (-0.07%)

13:26
11/20/17
11/20
13:26
11/20/17
13:26
Technical Analysis
Technical View: Analog Devices hits new 52-week high »

The stock is up over 3.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 09

    Jan

CVS

CVS Health

$70.05

-0.63 (-0.89%)

, AET

Aetna

$174.65

1.45 (0.84%)

13:25
11/20/17
11/20
13:25
11/20/17
13:25
Periodicals
CVS, Aetna could reach deal by end of November, WSJ reports »

Amazon (AMZN) threat is…

CVS

CVS Health

$70.05

-0.63 (-0.89%)

AET

Aetna

$174.65

1.45 (0.84%)

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

FB

Facebook

$179.00

-0.59 (-0.33%)

GOOG

Alphabet

$1,019.09

-13.41 (-1.30%)

GOOGL

Alphabet Class A

$1,035.89

-12.58 (-1.20%)

NFLX

Netflix

$193.20

-2.31 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

  • 29

    Nov

  • 29

    Nov

  • 12

    Dec

  • 18

    Mar

AMC

AMC Entertainment

$12.63

-0.32 (-2.47%)

13:25
11/20/17
11/20
13:25
11/20/17
13:25
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

13:25
11/20/17
11/20
13:25
11/20/17
13:25
Conference/Events
Cowen consumer analyst holds an analyst/industry conference call »

Consumer: Beverages,…

AUPH

Aurinia Pharmaceuticals

$5.14

-0.05 (-0.96%)

13:18
11/20/17
11/20
13:18
11/20/17
13:18
Conference/Events
Aurinia Pharmaceuticals management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

$NSD

NASDAQ Market Internals

13:17
11/20/17
11/20
13:17
11/20/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/20/17
11/20
13:16
11/20/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$108.82

-2.78 (-2.49%)

13:12
11/20/17
11/20
13:12
11/20/17
13:12
Periodicals
EA's 'Battlefront 2' physical sales 60% lower than 'Battlefront,' Eurogamer says »

Electronic Arts'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 30

    Jan

GES

Guess

$17.30

-0.36 (-2.04%)

13:10
11/20/17
11/20
13:10
11/20/17
13:10
Options
Defensive option play in Guess ahead of earnings »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:10
11/20/17
11/20
13:10
11/20/17
13:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

RGC

Regal Entertainment

$15.83

-0.34 (-2.10%)

13:05
11/20/17
11/20
13:05
11/20/17
13:05
Options
Regal Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$233.21

3.85 (1.68%)

13:03
11/20/17
11/20
13:03
11/20/17
13:03
Periodicals
Minn. seeks to add punitive damages to 3M suit, Bloomberg reports »

Minnesota State Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

MDT

Medtronic

$79.36

-0.13 (-0.16%)

, LOW

Lowe's

$81.60

1.38 (1.72%)

12:59
11/20/17
11/20
12:59
11/20/17
12:59
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$79.36

-0.13 (-0.16%)

LOW

Lowe's

$81.60

1.38 (1.72%)

ADI

Analog Devices

$90.42

-0.06 (-0.07%)

DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

HRL

Hormel Foods

$33.28

0.16 (0.48%)

CPB

Campbell Soup

$50.29

0.57 (1.15%)

BURL

Burlington Stores

$105.94

1.21 (1.16%)

SIG

Signet Jewelers

$76.49

-0.09 (-0.12%)

DSW

DSW

$22.42

0.27 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 01

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Jan

CMPR

Cimpress

$122.17

3.09 (2.59%)

12:58
11/20/17
11/20
12:58
11/20/17
12:58
Conference/Events
Cimpress management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

INTU

Intuit

$156.55

0.9 (0.58%)

, A

Agilent

$69.52

0.73 (1.06%)

12:58
11/20/17
11/20
12:58
11/20/17
12:58
Earnings
Notable companies reporting after market close »

Notable companies…

INTU

Intuit

$156.55

0.9 (0.58%)

A

Agilent

$69.52

0.73 (1.06%)

PANW

Palo Alto Networks

$142.68

-0.04 (-0.03%)

URBN

Urban Outfitters

$27.90

1.45 (5.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 30

    Nov

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

BBY

Best Buy

$56.62

0.79 (1.42%)

12:52
11/20/17
11/20
12:52
11/20/17
12:52
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

POST

Post Holdings

$81.06

0.11 (0.14%)

12:50
11/20/17
11/20
12:50
11/20/17
12:50
Recommendations
Post Holdings analyst commentary  »

Post Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$45.71

-0.005 (-0.01%)

12:50
11/20/17
11/20
12:50
11/20/17
12:50
Options
Call buyers in Coke after an Investor Day »

Call buyers in Coke after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFSI

AmTrust

$9.05

-0.06 (-0.66%)

12:48
11/20/17
11/20
12:48
11/20/17
12:48
Conference/Events
AmTrust management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TAL

TAL Education

$28.53

-1.23 (-4.13%)

12:45
11/20/17
11/20
12:45
11/20/17
12:45
Options
Tal Education Group call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.